Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Nurix Therapeutics, Inc.
Verismo Therapeutics
Incyte Corporation
University of Utah
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TCRx Therapeutics Co.Ltd
Otsuka Pharmaceutical Co., Ltd.
Calibr, a division of Scripps Research
Seagen Inc.
British Columbia Cancer Agency
Weill Medical College of Cornell University
Zumutor Biologics Inc.
Novartis
Pfizer
City of Hope Medical Center
Eli Lilly and Company
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
Nurix Therapeutics, Inc.
Fred Hutchinson Cancer Center
Eli Lilly and Company
AstraZeneca
Abramson Cancer Center at Penn Medicine
MEI Pharma, Inc.
Massachusetts General Hospital
BeOne Medicines
Atara Biotherapeutics
Cedars-Sinai Medical Center
University of Washington
Poseida Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Medical College of Wisconsin
Ascentage Pharma Group Inc.
National Institutes of Health Clinical Center (CC)
University of Utah
Newave Pharmaceutical Inc
Mayo Clinic
AbbVie
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
Roswell Park Cancer Institute
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Prelude Therapeutics